16,500 Shares in Grifols, S.A. (NASDAQ:GRFS) Purchased by Tidal Investments LLC

Tidal Investments LLC acquired a new position in shares of Grifols, S.A. (NASDAQ:GRFS) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 16,500 shares of the biotechnology company’s stock, valued at approximately $147,000.

Other institutional investors and hedge funds also recently bought and sold shares of the company. B. Riley Wealth Advisors Inc. acquired a new stake in shares of Grifols during the second quarter worth approximately $359,000. Stifel Financial Corp purchased a new stake in Grifols in the 3rd quarter worth approximately $1,043,000. Sei Investments Co. boosted its stake in shares of Grifols by 4.7% during the 2nd quarter. Sei Investments Co. now owns 2,209,547 shares of the biotechnology company’s stock valued at $13,931,000 after buying an additional 100,131 shares during the period. Melqart Asset Management UK Ltd purchased a new position in shares of Grifols during the 3rd quarter valued at $1,628,000. Finally, Hantz Financial Services Inc. acquired a new position in shares of Grifols in the second quarter worth $1,235,000.

Analysts Set New Price Targets

Separately, Berenberg Bank upgraded Grifols to a “strong-buy” rating in a research note on Tuesday, October 29th.

Grifols Trading Up 1.8 %

NASDAQ:GRFS opened at $7.82 on Thursday. The company has a market capitalization of $5.38 billion, a P/E ratio of 8.06 and a beta of 0.43. The stock’s 50 day moving average price is $8.31 and its 200 day moving average price is $8.12. The company has a debt-to-equity ratio of 1.11, a quick ratio of 0.79 and a current ratio of 2.26. Grifols, S.A. has a 52 week low of $5.30 and a 52 week high of $12.15.

About Grifols

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.